{
    "nct_id": "NCT04416984",
    "official_title": "A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)",
    "inclusion_criteria": "For subjects with LBCL:\n\n* Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse per WHO 2017\n* At least 1 measurable lesion at time of enrollment\n* Relapsed or refractory disease after at least 2 lines of chemotherapy\n* Absence of significant donor (product)-specific anti-HLA antibodies (DSA) at screening (Note: Only applicable for Phase 2)\n\nFor subjects with CLL/SLL:\n\n* Diagnosis of CLL/SLL\n* Relapsed/refractory disease\n* Subjects relapsed/refractory to BTKi therapy and high-risk disease\n* Subjects relapsed/refractory with 2 or more lines of therapy including BTKi and BCL-2 inhibitor (venetoclax)\n* At least 1 measurable lesion at time of enrollment\n\nFor all subjects:\n\n* Male or female subjects â‰¥18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n* Adequate hematological, renal, and liver function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active central nervous system (CNS) involvement by malignancy\n* Current thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy\n* Any other active malignancies that required systemic treatment within 3 years prior to enrollment\n* Radiation therapy within 2 weeks prior to ALLO-647\n* Prior irradiation to >25% of the bone marrow\n* Hypocellular bone marrow for age by institutional standard as determined from a bone marrow biopsy performed at time of screening (Note: Only applicable for Phase 2).\n* Autologous hematopoietic stem cell transplant (HSCT) within last 6 months (24 weeks)\n* Systemic anti-cancer therapy within 2 weeks prior to receiving ALLO-647",
    "miscellaneous_criteria": ""
}